免疫复合物介导的膜增生性肾小球肾炎与C3肾小球病的诊治挑战
本文综述免疫复合物介导的膜增生性肾小球肾炎(IC-MPGN)和C3肾小球病(C3G)的补体作用与组织病理学差异,通过七个病例讨论共识指南治疗推荐及临床实践中的诊断管理不确定性,强调多学科协作和知识缺口。
要点
- IC-MPGN和C3G是罕见补体介导肾病,临床与病理重叠。
- 诊断管理存在未满足需求,需多学科团队协作。
- 关键知识缺口包括鉴别诊断、病理机制和靶向治疗缺乏。
核心结论
- IC-MPGN和C3G诊断与管理仍面临挑战,需提高认识以优化靶向治疗和个体化管理。
研究设计与样本
- 综述总结了补体在IC-MPGN和C3G中的作用及关键组织病理学差异。
- 使用七个示例病例讨论共识指南治疗推荐及临床实践中的不确定性和考虑。
主要发现
- IC-MPGN和C3G罕见且临床、组织学和病理生理重叠,导致诊断和管理困难。
- 病例强调需要包括初级保健提供者、肾内科医生、肾脏病理学家和实验室科学家的多学科方法。
- 关键知识缺口包括鉴别诊断、潜在病理机制和缺乏针对疾病驱动因素的有效治疗。
临床怎么用
- 临床中应认识到IC-MPGN和C3G的罕见性和重叠特征,采用多学科协作进行诊断和管理。
局限性
- IC-MPGN和C3G的罕见性及知识缺口限制诊断和管理优化。
- 缺乏针对疾病驱动因素的有效治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) and complement 3 glomerulopathy (C3G) are rare, complement-mediated kidney diseases, previously classified under the group of kidney disorders termed membranoproliferative glomerulonephritis (MPGN) type 1, type 2, and type 3. Despite new advances in our understanding of IC-MPGN and C3G, several unmet needs persist in the diagnosis and management of patients with these nephropathies, due in part to their rarity and their overlapping clinical presentations, histologic features, and underlying pathophysiologies. This review summarizes our current understanding of the role of complement in IC-MPGN and C3G, and underlines the key histopathologic differences between the diseases. Using seven illustrative patient cases, we discuss consensus guideline treatment recommendations and the uncertainties, challenges, and considerations regarding the diagnosis and management of patients with IC-MPGN and C3G in clinical practice. The presented cases emphasize the need for a multidisciplinary approach encompassing primary care providers (PCPs), nephrologists, nephropathologists, and laboratory scientists. Key knowledge gaps are evaluated, including differential diagnoses, underlying pathologic mechanisms, and the lack of effective treatments targeting drivers of disease. As the therapeutic landscape evolves, an improved understanding of IC-MPGN and C3G is crucial to identifying optimal targeted-treatment strategies and facilitating a personalized approach to the management of these complex glomerular diseases.
引用
- Bomback AS, Charu V, Fakhouri F, et al. Challenges in the Diagnosis and Management of Immune Complex-Mediated Membranoproliferative Glomerulonephritis and Complement 3 Glomerulopathy. Kidney Int Rep. 2024. PMID: 39810761. doi:10.1016/j.ekir.2024.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。